Jim Simons Hutchmed (China) LTD Transaction History

Renaissance Technologies LLC

$70.6 Billion
Q3 2025

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Hutchmed (China) LTD stock. As of the latest transaction made, Renaissance Technologies LLC holds 131,000 shares of HCM stock, worth $1.98 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

131,000

Previous 129,000 1.55%

Holding current value

$1.98 Million

Previous $1.94 Million 6.29%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	BUY	$14.83 - $19.21 $29,660 - $38,420	2,000 Added 1.55%	131,000 $2.06 Million
Q2 2025 Aug 13, 2025	SELL	$11.81 - $17.72 $73,222 - $109,864	-6,200 Reduced 4.59%	129,000 $1.94 Million
Q1 2025 May 14, 2025	SELL	$13.09 - $16.75 $698,207 - $893,428	-53,339 Reduced 28.29%	135,200 $2.03 Million
Q4 2024 Feb 13, 2025	BUY	$14.25 - $21.35 $416,655 - $624,252	29,239 Added 18.35%	188,539 $2.72 Million
Q3 2024 Nov 13, 2024	BUY	$16.03 - $20.31 $448,840 - $568,680	28,000 Added 21.33%	159,300 $3.11 Million

Q2 2024 Aug 09, 2024	BUY	$16.36 - $21.78 $919,432 - $1.22 Million	56,200 Added 74.83%	131,300 $2.25 Million
Q1 2024 May 13, 2024	SELL	$12.08 - $18.56 $86,976 - $133,632	-7,200 Reduced 8.75%	75,100 $1.26 Million
Q4 2023 Feb 13, 2024	BUY	$16.25 - $20.23 $492,375 - $612,969	30,300 Added 58.27%	82,300 $1.49 Million
Q3 2023 Nov 14, 2023	SELL	$11.85 - $16.95 $40,906 - $58,511	-3,452 Reduced 6.23%	52,000 $881,000
Q2 2023 Aug 11, 2023	SELL	$10.78 - $17.73 $1.01 Million - $1.66 Million	-93,800 Reduced 62.85%	55,452 $665,000
Q1 2023 May 12, 2023	BUY	$13.02 - $19.87 $777,294 - $1.19 Million	59,700 Added 66.67%	149,252 $1.94 Million
Q4 2022 Feb 13, 2023	SELL	$7.65 - $15.51 $18,360 - $37,224	-2,400 Reduced 2.61%	89,552 $1.32 Million
Q3 2022 Nov 14, 2022	SELL	$8.63 - $15.52 $2.8 Million - $5.04 Million	-324,700 Reduced 77.93%	91,952 $815,000
Q2 2022 Aug 12, 2022	BUY	$8.59 - $20.77 $3.58 Million - $8.65 Million	416,652 New	416,652 $5.27 Million
Q1 2022 May 13, 2022	SELL	$15.52 - $35.65 $636,320 - $1.46 Million	-41,000 Closed	0 $0
Q4 2021 Feb 11, 2022	SELL	$28.89 - $35.33 $2.96 Million - $3.62 Million	-102,352 Reduced 71.4%	41,000 $1.44 Million
Q3 2021 Nov 12, 2021	SELL	$35.66 - $42.94 $2.46 Million - $2.96 Million	-69,000 Reduced 32.49%	143,352 $5.25 Million
Q2 2021 Aug 13, 2021	SELL	$23.7 - $39.27 $215,670 - $357,357	-9,100 Reduced 4.11%	212,352 $8.34 Million
Q1 2021 May 13, 2021	SELL	$27.01 - $36.8 $1.52 Million - $2.06 Million	-56,100 Reduced 20.21%	221,452 $6.26 Million
Q4 2020 Feb 10, 2021	SELL	$27.51 - $34.36 $1.6 Million - $1.99 Million	-58,048 Reduced 17.3%	277,552 $8.89 Million
Q3 2020 Nov 13, 2020	SELL	$25.8 - $34.61 $1.71 Million - $2.29 Million	-66,200 Reduced 16.48%	335,600 $10.8 Million
Q2 2020 Aug 13, 2020	BUY	$17.65 - $28.05 $995,459 - $1.58 Million	56,400 Added 16.33%	401,800 $11.1 Million
Q1 2020 May 14, 2020	BUY	$15.19 - $29.51 $732,158 - $1.42 Million	48,200 Added 16.22%	345,400 $6.17 Million
Q4 2019 Feb 13, 2020	BUY	$17.17 - $25.95 $2.38 Million - $3.59 Million	138,400 Added 87.15%	297,200 $7.45 Million
Q3 2019 Nov 13, 2019	BUY	$17.84 - $22.69 $1.99 Million - $2.53 Million	111,400 Added 235.02%	158,800 $2.83 Million
Q2 2019 Aug 12, 2019	BUY	$22.0 - $31.78 $81,400 - $117,586	3,700 Added 8.47%	47,400 $1.04 Million
Q1 2019 May 14, 2019	SELL	$21.27 - $30.58 $697,656 - $1 Million	-32,800 Reduced 42.88%	43,700 $1.34 Million
Q4 2018 Feb 13, 2019	BUY	$23.09 - $37.69 $1.77 Million - $2.88 Million	76,500 New	76,500 $1.77 Million

Others Institutions Holding HCM

# of Institutions

Shares Held

5.74M

Call Options Held

Put Options Held

View Full List

About HUTCHMED (China) Ltd

Ticker HCM
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 172,955,008
Market Cap $2.61B
Description
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...

More about HCM

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account